

NEW CUSTOMER DATA SHOWS APAS® DELIVERS PROVEN VALUE IN PHARMACEUTICAL MANUFACTURING

AstraZeneca, Bristol Myers Squibb and Pfizer present new performance data

Adelaide, Australia, 17 November 2025: Leaders in AI microbiology automation, Clever Culture Systems Ltd (ASX: CC5) (**CCS** or the **Company**), today announced that three of the world's largest pharmaceutical manufacturers, AstraZeneca, Bristol Myers Squibb and Pfizer, have presented new performance data highlighting their successful use of the APAS® Independence platform. The data was featured at recent international conferences held in Australia and the United States, further validating APAS® Independence as a trusted automation technology for pharmaceutical microbiology.

The data from these presentations will be presented at the Company's Shareholder Open Day held on 17 November 2025 and the studies are available on the Company's website, under the Scientific Library. To access the presentations please use the links below.

Highlights:

- **Pfizer present results from a large-scale evaluation study involving more than 6,000 microbiology plates from routine manufacturing operations, demonstrating the systems reliability and scalability**
- **AstraZeneca delivered an oral presentation outlining its global rollout of APAS® Independence across multiple manufacturing facilities, following successful validation and adoption**
- **Bristol Myers Squibb published performance data showcasing the success of the new APAS® contact plate analysis module, underscoring the platform's expanding utility for environmental monitoring**

Brent Barnes, CEO and Managing Director said:

"We pride ourselves in leading the way with a scientific and data driven approach to technology development. In the pharmaceutical industry robust performance data is critical for technology acceptance and adoption within the market. Having three major manufacturers share their positive experiences with APAS® at leading industry conferences is a powerful endorsement of the technology, and it demonstrates the tangible impact APAS® can deliver for other companies considering its integration and value in improving quality, efficiency and compliance within their manufacturing operations."

Pfizer: Case Study "Implementation of Automated EM Plate Reader" by Mark Gracie, LTS Manager

Conference: PDA Asia Pacific Aseptic Manufacturing Excellence Conference in Melbourne, Australia

Date: 13-14 October 2025

Presentation: [Here](#)

Pfizer presented findings from their evaluation of APAS® Independence with the 90mm settle plate analysis module as a case study on *new* innovations in sterile drug manufacturing. The study compared the results of APAS® to manual plate reading, covering over 6,000 culture plates collected in routine operations and specific plates prepared for challenge testing.

APAS® Independence achieved excellent performance, achieving 0% false negative results from samples collected in routine operations and demonstrated high usability from analysts.

AstraZeneca: Podium Presentation "A Global Approach to New Technology Introduction and Validation: Automated Colony Counting" by Phil Duncanson, PhD, Senior Director

Conference: Annual PDA Pharmaceutical Microbiology Conference (PDA Micro) in Washington, DC, USA

Date: 27-29 October 2025

Presentation: [Here](#)

AstraZeneca presented their approach to introducing new technologies, referencing APAS® Independence as a case study for global implementation. The presentation highlighted the strong technical performance of APAS® Independence demonstrated during AstraZeneca's validation of the technology and their approach to implementing APAS® for routine use within their environmental monitoring program.

Following successful validation, the technology has now been approved for global network rollout across AstraZeneca's largest manufacturing sites, with 9 instruments installed to date and a tenth instrument recently ordered.

Bristol Myers Squibb: Poster Presentation “Evaluating the APAS® Independence System for Automated Microbial Detection in Environmental Monitoring” by Jennifer Hester, Scientist

Conference: Annual PDA Pharmaceutical Microbiology Conference (PDA Micro) in Washington, DC, USA

Date: 27-29 October 2025

Poster: [Here](#)

The focus of Bristol Myers Squibb's poster was to evaluate the performance of APAS® Independence for automated colony counting, across a range of microbial organisms using both the settle plate (90mm) analysis module and the contact plate (55mm) analysis module. The results demonstrated APAS® system met all acceptance criteria for count accuracy.

Importantly, this study provides the first customer data validating the performance of the new contact plate analysis module, highlighting comparable strong performance to the existing settle plate analysis module.

Customer data set to accelerate global commercialisation activities

The presentation of customer data supporting the performance of the APAS® Independence represents an important commercial milestone for the Clever Culture Systems. Third party validation of the APAS® technology strengthen the Company's credibility with prospective customers by directly addressing a key consideration during the sales process.

The Company's strategic collaboration with major pharmaceutical manufacturers who are the leaders in the industry provides influential and highly impactful voice of customer support and further reinforces a reputation as the industry leader in artificial intelligence driven microbiology automation.

The combined presentations from AstraZeneca, Bristol Myers Squibb and Pfizer highlight different aspects of the APAS® technology implementation, such as growth differentiation, counting performance and technology adoption, demonstrating strong performance, scalability and reliability across differing pharmaceutical manufacturing environments. The validation from three global leaders adds significant depth and credibility to the user data supporting the performance of the technology.

Approved for release by the CCS Board.

– ENDS –

About Clever Culture Systems

Clever Culture Systems (CCS) provides intelligent automation solutions to microbiology laboratories. Based in Adelaide, South Australia, the Company has developed a best-in-class technology, the Automated Plate Assessment System (APAS® Independence), using artificial intelligence and machine learning software to automate the imaging, analysis and interpretation of microbiology culture plates. The technology remains the only US FDA-cleared artificial intelligence technology for automated culture plate reading. The product is currently being sold to microbiology laboratories in the pharmaceutical manufacturing sector for the reading of environmental monitoring culture plates and to clinical laboratories as an in vitro diagnostic for infectious diseases. Thermo Fisher Scientific, Inc is exclusive distributor of the APAS® Independence to clinical customers in the United States and selected countries in Europe.

INVESTOR ENQUIRIES

Clever Culture Systems
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@cleverculturesystems.com